FabP1 1013
Alternative Names: Fab-P1-1013Latest Information Update: 26 Aug 2022
At a glance
- Originator FatiAbGen
- Class Antiallergics; Recombinant proteins
- Mechanism of Action IgE receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Hypersensitivity
Most Recent Events
- 26 Aug 2022 FabP1 1013 is available for licensing as of 26 Aug 2022. http://www.fatiabgen.com/sub_fatiabgen.php
- 26 Aug 2022 Early research in Hypersensitivity in South Korea (Parenteral), as of August 2022 (FatiAbGen website, August 2022)
- 26 Aug 2022 FatiAbGen plans to submit IND application for Hypersensitivity, in Q3 2024